It costs, on average, $2.6 billion and over a decade to bring a single drug to market. Roughly 90% of drug candidates fail in clinical trials. And yet, the pressure to innovate faster, spend smarter, and outmanoeuvre competitors has never been more intense. Molecular modelling isn't just a scientist's tool anymore. It's a strategic asset, one that is quietly rewriting the rules of drug discovery, pipeline prioritisation, manufacturing efficiency, and regulatory success. At its core, molecular modelling is the use of computational techniques to simulate, visualise, and analyse the behaviour of molecules, particularly how drugs interact with biological targets at an ato...
